CMDNChina Myeloma Digital Network

Multiple Myeloma Clinical Guidelines
You never fight alone — we guide every step

Multiple myeloma is now a highly manageable condition.
Hope and breakthroughs are always within reach.

Strictly distilled from authoritative guidelines

👇 Please select your current stage

A relapse is not the end of the road. We have an ever-expanding arsenal of new immunotherapies to fight back.

Essential Knowledge for This Stage

What to Do When Myeloma Relapses

Understanding biochemical vs. clinical relapse and all available treatment lines.

"A biochemical relapse alone does not always require immediate treatment; your doctor has an expanding playbook of targeted options."

What happens when it comes back?

Understanding class-switching and next-line therapies.

"A biochemical relapse alone does not always require immediate treatment; your doctor may watch and wait."

Tracking the M-Protein

How SPEP and UPEP track the return of myeloma.

"Regular blood and urine tests are your most reliable early warning system."

Do I need another biopsy?

Why repeating the bone marrow biopsy is crucial at relapse.

"A repeat biopsy helps your doctor see if the myeloma has developed new, higher-risk genetic mutations."

Risk Re-Evaluation at Relapse

How cytogenetic shifts and R2-ISS scores guide next-line precision therapy.

"Re-staging genetics at relapse ensures your team selects the most powerful targeted drug combination."

Which scans are best?

The role of PET-CT and MRI in detecting active disease.

"PET-CT is the gold standard for finding myeloma that has grown outside of the bone marrow."

Should I join a clinical trial?

Accessing tomorrow's CAR-T and bispecific therapies today.

"Clinical trials offer you early access to highly effective, cutting-edge therapies that aren't yet widely available."

Curative Potential in Relapse

How CAR-T cell therapies and bispecific antibodies are delivering durable long-term remissions.

"Even in multi-relapsed disease, single-infusion CAR-T therapies are achieving 5-year overall survival rates over 75%."

What is CAR T-Cell Therapy?

How reprogrammed immune cells achieve deep remissions in relapsed and refractory myeloma.

"CAR-T re-engineers your own T-cells into living precision weapons, delivering complete response rates over 75%."

When is the Best Time for CAR-T?

Why receiving cellular therapy at first relapse maximizes immune fitness and survival.

"Deploying CAR-T at first relapse reduces the risk of progression or death by 73%."

Trial Matching After Refractoriness

Navigating studies by prior daratumumab and lenalidomide exposure.

"Prior drug refractoriness is the precise qualification ticket required to enter cutting-edge trials."

CAR-T vs Bispecifics in China

Comparing treatment kinetics, hospital stays, and target sequencing.

"Weighing single-infusion cellular therapy against off-the-shelf continuous bispecific antibodies."

Post-CAR-T Relapse Trials

Overcoming antigen escape via GPRC5D and multispecific antibodies.

"Relapse after BCMA CAR-T is not the end of the road: alternative targets offer deep second remissions."

How to Join Trials in China

Official registry portals, informed consent rights, and cost protections.

"Joining a trial is an established medical pathway, protected by national GCP regulations."

Patient Advocacy in China

Nonprofit peer support, charitable PAP programs, and digital tracking.

"You are never alone: free nonprofit advocacy networks protect families from predatory commercial brokers."

Knowledge Atlas Index

Quickly find all required clinical information by category.

Medical Categories

Diagnosis & Monitoring8 Topics

From lab reports to MRD

What is Multiple Myeloma?

Understanding the basics of plasma cells and CRAB criteria.

How do I read my lab reports?

A beginner's guide to SPEP, UPEP, and bone marrow biopsy results.

Am I high-risk or standard-risk?

Decoding your FISH test and cytogenetics.

Risk Re-Evaluation at Relapse

How cytogenetic shifts and R2-ISS scores guide next-line precision therapy.

Tracking the M-Protein

How SPEP and UPEP track the return of myeloma.

Do I need another biopsy?

Why repeating the bone marrow biopsy is crucial at relapse.

Which scans are best?

The role of PET-CT and MRI in detecting active disease.

What is MRD Negative?

Understanding Minimal Residual Disease testing.

Sincere thanks to the following authoritative institutions
for their academic support:

Lighting the hope of survival
for myeloma patients globally

Disclaimer: All disease knowledge, guideline interpretations, and treatment processes provided on this site are for learning and reference only, and do not constitute any medical advice or professional diagnosis. The condition of each patient is unique. For specific treatment plans and medication decisions, please be sure to follow the guidance of your attending physician or professional medical team.

Get Support